Taiwan Bio Therapeutics Co., Ltd. has entered into a strategic partnership with U.S.-based TRACT Therapeutics, focusing on cell therapies aimed at preventing allograft rejection in solid organ transplants. Under the agreement, Taiwan Bio will leverage its manufacturing expertise in cell therapy to enhance TRACT’s immune-modulating regulatory T cell therapy platform.
The collaboration will kick off with TRACT’s autologous Treg product, TregCel, which is set to enter a Phase II clinical trial. This study will investigate the potential to reduce the reliance on immunosuppressant drugs in living donor kidney transplant recipients across both the United States and Taiwan.- Flcube.com
